We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00227188
First Posted: September 27, 2005
Last Update Posted: November 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
September 13, 2005
September 27, 2005
November 29, 2012
May 2003
December 2005   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00227188 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Samples without DNA
Non-Probability Sample
All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.
Invasive Pneumococcal Disease
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR
1
Children from 0-5 years of age evaluated for IPD
Intervention: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
408
December 2005
December 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
Sexes Eligible for Study: All
up to 5 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00227188
0887-101317
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012